EpiVax inc., led by CEO/CSO, Dr. Annie De Groot, MD, has a number of publications citing the process, and results, of deimmunzaiton by epitope modification for reduced immunologic potential in-vitro, in-vivo and ex-vivo.
•
In: Charles Janeway, Paul Travers, Mark Walport, Mark Shlomchik: Immunobiology. The Immune System in Health and Disease. 6th Edition.